https://www.targetedonc.com/view/bla-for-remestemcel-l-to-treat-pediatric-sr-agvhd-resubmitted-to-fda
Summary below of the phase 3 GVHD001/002 clinical trial (NCT02336230) which supports the BLA.
Please fix if you find holes.
Outcome Measure Result Overall Response Rate (ORR) at Day 28 70.4% Comparison to Control ORR (P-value) Exceeded control value of 45% (P = .0003) Survival Rate at Day 100 (Responders) 87% Survival Rate at Day 100 (Non-responders) 47% Comparison to Best Available Therapy Response at Day 28: 67% vs. 10% in control group Survival at Day 180: 67% vs. 10% in control group Dosage Regimen Intravenous remestemcel-L at 2 x 10^6 MSC/kg twice per week for 4 weeks Patient Eligibility Ages 2 months to 17 years, grade B-D aGVHD requiring systemic corticosteroid therapy, adequate performance status and renal function Trial Endpoints Primary: ORR at 28 days Secondary: OS at 100 days, ORR at 56 and 100 days
- Forums
- ASX - By Stock
- Cell Therapy News/Articles
https://www.targetedonc.com/view/bla-for-remestemcel-l-to-treat-p...
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
91.5¢ |
Change
0.010(1.10%) |
Mkt cap ! $1.044B |
Open | High | Low | Value | Volume |
93.0¢ | 93.5¢ | 90.5¢ | $4.638M | 5.036M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 152669 | 91.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
92.5¢ | 51069 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 152669 | 0.910 |
9 | 292808 | 0.905 |
19 | 320866 | 0.900 |
4 | 1016220 | 0.895 |
5 | 37990 | 0.890 |
Price($) | Vol. | No. |
---|---|---|
0.925 | 51069 | 3 |
0.930 | 211805 | 12 |
0.935 | 70553 | 3 |
0.940 | 103316 | 5 |
0.945 | 26067 | 3 |
Last trade - 16.10pm 07/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |